Risedronate (NE-58095) is a third generation bisphosphonate bone-resorption inhibitor and osteogenesis stimulator under development by Norwich-Eaton (a subsidiary of Procter and Gamble) for the potential treatment of various bone diseases including osteoporosi... ...
